Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of EpendymomaPRNewsWire • 04/14/21
Moleculin Biotech's Stock Is Trading Higher On Accelerated Review Tag For Annamycin In Connective Tissue CancerBenzinga • 03/30/21
Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung MetastasesPRNewsWire • 03/30/21
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020PRNewsWire • 03/24/21
Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung MetastasesPRNewsWire • 02/08/21
Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma TrialPRNewsWire • 02/01/21
Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue SarcomasPRNewsWire • 12/29/20
Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung MetastasesPRNewsWire • 12/17/20
Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual ConferencePRNewsWire • 12/03/20
Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066PRNewsWire • 12/01/20
Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AMLPRNewsWire • 11/19/20
Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020PRNewsWire • 11/13/20
Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19PRNewsWire • 10/29/20
Moleculin to Participate in Panel at ROTH Capital's "COVID-19 Therapeutics in Development" Healthcare EventPRNewsWire • 10/27/20
